Corpus ID: 54635607

Bioanalytical Approach to the Interaction of Novel sym-Triazine Derivatives with Alzheimer ’ s disease biomarkers

@inproceedings{Liu2015BioanalyticalAT,
  title={Bioanalytical Approach to the Interaction of Novel sym-Triazine Derivatives with Alzheimer ’ s disease biomarkers},
  author={A. Liu},
  year={2015}
}
  • A. Liu
  • Published 2015
    • Alzheimer’s Disease (AD) is a complex neurological disorder affecting an increasing number of people worldwide. The amyloid hypothesis is the most widely accepted theory for the cause of AD and states that the main origin of the disease stems from the mis-folding and accumulation of the amyloid-beta peptide (Aβ). There is currently no cure for the disease, however, drugs are available to mitigate the symptoms. Multi-target directed ligands (MTDLs) have been implemented as a novel drug design… CONTINUE READING
    tspace.library.utoronto.ca

    References

    SHOWING 1-10 OF 170 REFERENCES
    sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.
    • 21
    • Highly Influential
    Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease.
    • 13
    Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity.
    • 56
    Multi-target-directed ligands in Alzheimer's disease treatment.
    • 171
    Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
    • 164
    Disease-modifying treatments for Alzheimer’s disease
    • 109
    • PDF
    Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
    • 134
    Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
    • 309
    Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.
    • 234
    Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.
    • 789